Developer docs
API playgroundTry for free, no card

Search company profiles

MBX Biosciences

Full company profile

uuid000034l

Namestring
MBX Biosciences
Legal namestring
MBX Biosciences, Inc.
Websiteurl
mbxbio.com
Company typeenum
Public
Founded yearint
2019
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCarmel, United States
HQ citystring
Carmel
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision peptide therapeutics, endocrine disorder treatments, metabolic disease therapies, peptide hormone engineering, clinical-stage biopharmaceutical
Industry5 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAEAHAG
Mental Health Parity (MHPAEA) Compliance & Reporting
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAHAAAJ
Companion Diagnostics (CDx) & Precision Medicine IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAANAB
Pharmacogenomics (PGx) Decision Support
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Endocrine and Metabolic Disease Therapeutics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pre-revenue / No product revenue
TypeSubscription Recurring
Description

MBX Biosciences is a clinical-stage biopharmaceutical company with no approved products and no current product revenue. Operations are funded through equity financing (Series B $115M, Series C $63.5M, ATM offering ~$87.1M) with cumulative funding of over $213 million as of August 2024.

ibj.com
2Future potential product sales (post-approval)
TypeHardware Sales
Description

Future revenue from canvuparatide (MBX 2109) for hypoparathyroidism, with analysts modeling peak worldwide sales exceeding $3 billion (Citizens Financial Group). Future product revenue expected from MBX 4291 and MBX 5765 obesity candidates and other pipeline assets once approved.

in.investing.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1Clinical-stage biotech — no product pricing publicly disclosed; stock ATM offering at $38.76 VWAP.
ModelOtherBilling cadencePay-as-you-go
Notes

Quote-based / Not publicly disclosed for products. At-the-market stock offering: 2,250,986 shares at $38.76 volume-weighted average price, ~$87.1M gross proceeds.

in.investing.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

MBX Biosciences is a clinical-stage biopharmaceutical company developing a portfolio of investigational precision endocrine peptide (PEP) therapeutics for endocrine and metabolic disorders. Its lead clinical asset is canvuparatide (MBX 2109), a once-weekly subcutaneous parathyroid hormone (PTH) replacement therapy for chronic hypoparathyroidism that has completed a Phase 2 Avail trial and is advancing into a Phase 3 trial planned for Q3 2026. The pipeline also includes MBX 4291 (GLP-1/GIP co-agonist prodrug for obesity with once-monthly dosing target), MBX 5765 (amycretin prodrug combining GLP-1, GIP, glucagon, and amylin/calcitonin activity), MBX 6XXX (GLP-1/GIP/GCGR triple-agonist prodrug), and imapextide (MBX 1416), a long-acting GLP-1 receptor antagonist that reported proof of concept in post-bariatric hypoglycemia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 63% responder rate at 12 weeks (vs. 31% placebo) in Phase 2 Avail trial of canvuparatide
+4 more records
Product overview1 text field

MBX Biosciences is a clinical-stage biopharmaceutical company built around a single unified proprietary discovery and engineering platform — the Precision Endocrine Peptide (PEP™) platform — from which a portfolio of named product candidates is being advanced. The lead clinical asset, Canvuparatide (MBX 2109), is a once-weekly PTH replacement therapy for chronic hypoparathyroidism advancing into Phase 3. The obesity portfolio is a modular set of differentiated candidates generated by the same platform: MBX 4291, a long-acting GLP-1/GIP co-agonist prodrug in Phase 1 with a once-monthly dosing target; MBX 5765, a recently nominated amycretin prodrug entering IND-enabling studies; and MBX 6XXX, a GLP-1/GIP/GCGR triple-agonist prodrug in discovery. The portfolio also includes Imapextide (MBX 1416), a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia that reported proof of concept. Together, the PEP platform and its product candidates (Canvuparatide, MBX 4291, MBX 5765, MBX 6XXX, Imapextide) form a coordinated platform-plus-candidates architecture aimed at endocrine and metabolic disorders.

Product and service5 records
1Canvuparatide (MBX 2109)
CategoryClinical candidate — chronic hypoparathyroidism (rare endocrine disease)
Description

Investigational once-weekly subcutaneous parathyroid hormone (PTH) replacement therapy designed to provide continuous, infusion-like PTH exposure for the treatment of chronic hypoparathyroidism in adults. Phase 2 Avail trial showed 63% responder rate at 12 weeks vs. 31% placebo, with one-year open-label extension data demonstrating 57% responder rate and 90% patient retention and sustained calcium normalization plus improved kidney function. Has received FDA and EMA orphan drug designation.

2MBX 4291
CategoryClinical candidate — obesity (metabolic disease)
Description

Long-acting Precision Endocrine Peptide (PEP) GLP-1/GIP co-agonist prodrug designed for potential once-monthly subcutaneous dosing in adult obesity. Preliminary Phase 1 MAD data demonstrated 7% mean weight loss at 8 weeks (range 0–16%) with a half-life of approximately 26 days supporting once-monthly dosing; full 12-week MAD Part C data expected Q4 2026.

3MBX 5765
CategoryPreclinical candidate — obesity (metabolic disease)
Description

Lead amycretin prodrug development candidate on the PEP platform. A single peptide construct combining GLP-1, GIP, glucagon, and dual amylin and calcitonin receptor agonist (DACRA) activity, designed for once-monthly subcutaneous dosing, superior efficacy, and improved tolerability in obesity. IND-enabling studies planned to begin in Q2 2026.

4MBX 6XXX
CategoryDiscovery candidate — obesity (metabolic disease)
Description

GLP-1/GIP/GCGR (glucagon receptor) triple-agonist prodrug being developed on the PEP platform as a potential treatment for obesity. Triple G prodrug candidate nomination is expected in Q3 2026.

5Imapextide (MBX 1416)
CategoryClinical candidate — post-bariatric hypoglycemia (rare metabolic disease)
Description

Long-acting GLP-1 receptor antagonist (PEP) evaluated in a Phase 1 trial for post-bariatric hypoglycemia, a complication of bariatric surgery characterized by dangerously low blood sugar. The Phase 1 trial completed the final subject's last visit in November 2024; the company reported imapextide achieved proof of concept in this indication in May 2026.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical and early-commercial stage biotech developing TransCon PTH (palopegteriparatide) for chronic hypoparathyroidism — the most direct competitor to canvuparatide in the same indication with similar PTH replacement mechanism.

TypeDirect peer
Description

Clinical-stage rare endocrine disease biotech (paltusotine for acromegaly) with comparable size, stage, and orphan-disease strategy focused on peptide therapeutics for endocrine disorders.

TypeDirect peer
Description

Clinical-stage biotech developing oral and non-injectable peptide candidates for endocrine and metabolic diseases including obesity (GSBR-1290), closely comparable in therapeutic focus and modality to MBX's PEP-derived candidates.

TypeDirect peer
Description

Clinical-stage biotech developing peptide-based therapies for metabolic diseases including VK2735 (GLP-1/GIP dual agonist) for obesity — directly comparable to MBX 4291 in mechanism and indication.

TypeDirect peer
Description

Commercial-stage rare endocrine disease biotech (IMCIVREE / setmelanotide for MC4R pathway obesities) with overlapping rare-endocrine specialty physician call point and orphan-drug commercial model.

TypeBroad incumbent
Description

Established peptide therapeutics company with a broader pipeline across metabolic disease (dasiglucagon for hypoglycemia) — comparable in peptide-platform focus but more mature with multiple clinical/commercial programs.

TypeDirect peer
Description

Clinical and early-commercial rare disease biotech (diazoxide choline extended-release for Prader-Willi syndrome hyperphagia) — comparable size, stage, and rare-endocrine metabolic focus.

TypeBroad incumbent
Description

Commercial rare disease biotech with multiple approved biologics and peptide therapeutics — relevant comparable for rare-disease commercial launch infrastructure and orphan drug strategy.

TypeBroad incumbent
Description

Incumbent leader in obesity with Mounjaro/Zepbound (tirzepatide) and next-generation GLP-1 candidates — sets the competitive benchmark MBX 4291 and MBX 5765 must overcome in obesity.

TypeBroad incumbent
Description

Incumbent leader in diabetes and obesity (Ozempic/Wegovy) with established global commercial footprint — sets the competitive benchmark and scale of resources any new obesity entrant must match.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MBX Biosciences

Endocrine and Metabolic Disease Therapeuticsmbxbio.com

MBX Biosciences firmographics

Firmographics
Name
MBX Biosciences
Legal name
MBX Biosciences, Inc.
Website
https://mbxbio.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

MBX Biosciences industry classification

Industry
Product category
Endocrine and Metabolic Disease Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAEAHAG
Mental Health Parity (MHPAEA) Compliance & Reporting
SECONDARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAHAAAJ
Companion Diagnostics (CDx) & Precision Medicine IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAANAB
Pharmacogenomics (PGx) Decision Support

Keywords

  • Precision peptide therapeutics
  • Endocrine disorder treatments
  • Metabolic disease therapies
  • Peptide hormone engineering
  • Clinical-stage biopharmaceutical

Where MBX Biosciences is headquartered

Location

Headquarters

HQ city
Carmel
HQ country
United States
HQ region
North America

Offices2 records

Markets served

MBX Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pre-revenue / No product revenue: MBX Biosciences is a clinical-stage biopharmaceutical company with no approved products and no current product revenue. Operations are funded through equity financing (Series B $115M, Series C $63.5M, ATM offering ~$87.1M) with cumulative funding of over $213 million as of August 2024.
  2. Future potential product sales (post-approval): Future revenue from canvuparatide (MBX 2109) for hypoparathyroidism, with analysts modeling peak worldwide sales exceeding $3 billion (Citizens Financial Group). Future product revenue expected from MBX 4291 and MBX 5765 obesity candidates and other pipeline assets once approved.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goClinical-stage biotech — no product pricing publicly disclosed; stock ATM offering at $38.76 VWAP.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels8 records

MBX Biosciences product offering

Product offering

Core offering

MBX Biosciences is a clinical-stage biopharmaceutical company developing a portfolio of investigational precision endocrine peptide (PEP) therapeutics for endocrine and metabolic disorders. Its lead clinical asset is canvuparatide (MBX 2109), a once-weekly subcutaneous parathyroid hormone (PTH) replacement therapy for chronic hypoparathyroidism that has completed a Phase 2 Avail trial and is advancing into a Phase 3 trial planned for Q3 2026. The pipeline also includes MBX 4291 (GLP-1/GIP co-agonist prodrug for obesity with once-monthly dosing target), MBX 5765 (amycretin prodrug combining GLP-1, GIP, glucagon, and amylin/calcitonin activity), MBX 6XXX (GLP-1/GIP/GCGR triple-agonist prodrug), and imapextide (MBX 1416), a long-acting GLP-1 receptor antagonist that reported proof of concept in post-bariatric hypoglycemia.

Product overview

MBX Biosciences is a clinical-stage biopharmaceutical company built around a single unified proprietary discovery and engineering platform — the Precision Endocrine Peptide (PEP™) platform — from which a portfolio of named product candidates is being advanced. The lead clinical asset, Canvuparatide (MBX 2109), is a once-weekly PTH replacement therapy for chronic hypoparathyroidism advancing into Phase 3. The obesity portfolio is a modular set of differentiated candidates generated by the same platform: MBX 4291, a long-acting GLP-1/GIP co-agonist prodrug in Phase 1 with a once-monthly dosing target; MBX 5765, a recently nominated amycretin prodrug entering IND-enabling studies; and MBX 6XXX, a GLP-1/GIP/GCGR triple-agonist prodrug in discovery. The portfolio also includes Imapextide (MBX 1416), a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia that reported proof of concept. Together, the PEP platform and its product candidates (Canvuparatide, MBX 4291, MBX 5765, MBX 6XXX, Imapextide) form a coordinated platform-plus-candidates architecture aimed at endocrine and metabolic disorders.

Differentiator

Problem solved

Functional benefit

Products and services

  • Canvuparatide (MBX 2109) Investigational once-weekly subcutaneous parathyroid hormone (PTH) replacement therapy designed to provide continuous, infusion-like PTH exposure for the treatment of chronic hypoparathyroidism in adults. Phase 2 Avail trial showed 63% responder rate at 12 weeks vs. 31% placebo, with one-year open-label extension data demonstrating 57% responder rate and 90% patient retention and sustained calcium normalization plus improved kidney function. Has received FDA and EMA orphan drug designation.
  • MBX 4291 Long-acting Precision Endocrine Peptide (PEP) GLP-1/GIP co-agonist prodrug designed for potential once-monthly subcutaneous dosing in adult obesity. Preliminary Phase 1 MAD data demonstrated 7% mean weight loss at 8 weeks (range 0–16%) with a half-life of approximately 26 days supporting once-monthly dosing; full 12-week MAD Part C data expected Q4 2026.
  • MBX 5765 Lead amycretin prodrug development candidate on the PEP platform. A single peptide construct combining GLP-1, GIP, glucagon, and dual amylin and calcitonin receptor agonist (DACRA) activity, designed for once-monthly subcutaneous dosing, superior efficacy, and improved tolerability in obesity. IND-enabling studies planned to begin in Q2 2026.
  • MBX 6XXX GLP-1/GIP/GCGR (glucagon receptor) triple-agonist prodrug being developed on the PEP platform as a potential treatment for obesity. Triple G prodrug candidate nomination is expected in Q3 2026.
  • Imapextide (MBX 1416) Long-acting GLP-1 receptor antagonist (PEP) evaluated in a Phase 1 trial for post-bariatric hypoglycemia, a complication of bariatric surgery characterized by dangerously low blood sugar. The Phase 1 trial completed the final subject's last visit in November 2024; the company reported imapextide achieved proof of concept in this indication in May 2026.

Quantifiable outcome

  • 63% responder rate at 12 weeks (vs. 31% placebo) in Phase 2 Avail trial of canvuparatide
  • +4 more outcomes

Companies that use MBX Biosciences

Customer profile

Segments4 records

Ideal customer profiles3 records

MBX Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

MBX Biosciences partnerships and signals

Strategic signal

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

MBX Biosciences competitors and assessment

Company assessment

Direct peers

  • Ascendis Pharma: Clinical and early-commercial stage biotech developing TransCon PTH (palopegteriparatide) for chronic hypoparathyroidism — the most direct competitor to canvuparatide in the same indication with similar PTH replacement mechanism.
  • Crinetics Pharmaceuticals: Clinical-stage rare endocrine disease biotech (paltusotine for acromegaly) with comparable size, stage, and orphan-disease strategy focused on peptide therapeutics for endocrine disorders.
  • Structure Therapeutics: Clinical-stage biotech developing oral and non-injectable peptide candidates for endocrine and metabolic diseases including obesity (GSBR-1290), closely comparable in therapeutic focus and modality to MBX's PEP-derived candidates.
  • Viking Therapeutics: Clinical-stage biotech developing peptide-based therapies for metabolic diseases including VK2735 (GLP-1/GIP dual agonist) for obesity — directly comparable to MBX 4291 in mechanism and indication.
  • Rhythm Pharmaceuticals: Commercial-stage rare endocrine disease biotech (IMCIVREE / setmelanotide for MC4R pathway obesities) with overlapping rare-endocrine specialty physician call point and orphan-drug commercial model.
  • Soleno Therapeutics: Clinical and early-commercial rare disease biotech (diazoxide choline extended-release for Prader-Willi syndrome hyperphagia) — comparable size, stage, and rare-endocrine metabolic focus.

Broad incumbents

  • Zealand Pharma: Established peptide therapeutics company with a broader pipeline across metabolic disease (dasiglucagon for hypoglycemia) — comparable in peptide-platform focus but more mature with multiple clinical/commercial programs.
  • Ultragenyx Pharmaceutical: Commercial rare disease biotech with multiple approved biologics and peptide therapeutics — relevant comparable for rare-disease commercial launch infrastructure and orphan drug strategy.
  • Eli Lilly: Incumbent leader in obesity with Mounjaro/Zepbound (tirzepatide) and next-generation GLP-1 candidates — sets the competitive benchmark MBX 4291 and MBX 5765 must overcome in obesity.
  • Novo Nordisk: Incumbent leader in diabetes and obesity (Ozempic/Wegovy) with established global commercial footprint — sets the competitive benchmark and scale of resources any new obesity entrant must match.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

MBX Biosciences social profiles

Digital presence

MBX Biosciences compliance and trust

Trust signal

Compliance3 records

MBX Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MBX Biosciences leadership team

Management profile

Number of profiles

Profiles9 records

MBX Biosciences funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MBX Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MBX Biosciences

What does MBX Biosciences do?

MBX Biosciences is a clinical-stage biopharmaceutical company developing a portfolio of investigational precision endocrine peptide (PEP) therapeutics for endocrine and metabolic disorders. Its lead clinical asset is canvuparatide (MBX 2109), a once-weekly subcutaneous parathyroid hormone (PTH) replacement therapy for chronic hypoparathyroidism that has completed a Phase 2 Avail trial and is advancing into a Phase 3 trial planned for Q3 2026. The pipeline also includes MBX 4291 (GLP-1/GIP co-agonist prodrug for obesity with once-monthly dosing target), MBX 5765 (amycretin prodrug combining GLP-1, GIP, glucagon, and amylin/calcitonin activity), MBX 6XXX (GLP-1/GIP/GCGR triple-agonist prodrug), and imapextide (MBX 1416), a long-acting GLP-1 receptor antagonist that reported proof of concept in post-bariatric hypoglycemia.

Is MBX Biosciences a public or private company?

MBX Biosciences is a public company. It is classified as public and is currently operating.

When was MBX Biosciences founded?

MBX Biosciences was founded in 2019. It employs 51 to 100 people.

Where is MBX Biosciences based?

MBX Biosciences is headquartered in Carmel, United States, in the North America region.

How does MBX Biosciences make money?

Two revenue lines are on record. Pre-revenue / No product revenue is the primary driver. The others are future potential product sales (post-approval).

Who are MBX Biosciences's main competitors?

Direct peers on record are Ascendis Pharma, Crinetics Pharmaceuticals, Structure Therapeutics, Viking Therapeutics, Rhythm Pharmaceuticals and Soleno Therapeutics. Broad incumbents are Zealand Pharma, Ultragenyx Pharmaceutical, Eli Lilly and Novo Nordisk.

Does MBX Biosciences have an API?

No public API is recorded for MBX Biosciences.

What industry is MBX Biosciences in?

MBX Biosciences's product category is Endocrine and Metabolic Disease Therapeutics. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAEAHAG, Mental Health Parity (MHPAEA) Compliance & Reporting. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsMBX Biosciences (NASDAQ:MBX) Now Covered by HC WainwrightHC Wainwright initiated coverage on MBX Biosciences with a buy rating and a $90 price target. The stock has a consensus rating of Moderate Buy with an average target of $87.30, and the company reported a loss of $1.29 per share for the quarter. CEO Steven Hoerter sold 4,893 shares at $54.82.Investing.comCitizens reiterates MBX Biosciences stock rating on GLP agonist dataCitizens reiterated a Market Outperform rating on MBX Biosciences with an $86 price target, implying about 49% upside from the current $57.72. The stock has surged 135% over the past year, and the firm noted Blackstone's $1.5B investment in Pfizer's GLP agonist. MBX-4291's Phase 1 data could drive shares higher.Simply Wall StMBX Biosciences (MBX) Starts Phase 3 Trial, Is The Stock Still A Bargain?MBX Biosciences began its Phase 3 oPTimize trial for weekly canvuparatide in chronic hypoparathyroidism, with upcoming obesity data and leadership hires. The stock has gained 84.39% year-to-date, trading 41% below the average analyst price target, with a fair value of $95.70 versus a last close of $56.33.Investing.comMBX Biosciences at Guggenheim: rare disease gains, obesity betsMBX Biosciences presented at the Guggenheim conference, saying its rare-disease program canvuparatide entered Phase III in chronic hypoparathyroidism after Phase II showed sustained benefit. Its obesity candidate MBX 4291 showed 7% weight loss at eight weeks in early blinded data, with a 26-day half-life supporting monthly dosing. Management said the obesity franchise may need a partner to reach full potential.Simply Wall StBigger Losses Could Test The Case For MBX Biosciences StockMBX Biosciences reported a Q3 2026 net loss of $62.42 million and a nine-month loss of $123.03 million. The widening losses reflect continued investment in its endocrine and metabolic pipeline, with the oPTimize Phase III trial for canvuparatide as the key operational catalyst. Analysts project revenue of $92.9 million and earnings of $16.0 million by 2029, implying a need for about $120 million in earnings improvement.YahooMBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate HighlightsMBX Biosciences reported Q3 2026 results, including a $62.4 million net loss and $481.6 million in cash and investments. The company initiated its pivotal Phase 3 oPTimize trial of once-weekly canvuparatide and expects to report unblinded 12-week MAD data for MBX 4291 in Q4 2026.MarketBeat53,077 Shares of MBX Biosciences, Inc. $MBX Purchased by Sowell Financial Services LLCSowell Financial Services acquired a new stake in MBX Biosciences, purchasing 53,077 shares valued at approximately $3.11 million in Q3. The company reported a loss of $0.78 per share for the quarter, missing estimates, and analysts have a consensus "Moderate Buy" rating with an average price target of $87.00.MarketBeatSowell Financial Services LLC Purchases 53,077 Shares of MBX Biosciences, Inc. $MBXSowell Financial Services LLC purchased 53,077 shares of MBX Biosciences in Q3, valued at about $3.11 million. The company reported a Q2 loss of $0.78 per share, missing estimates, and analysts have an average "Moderate Buy" rating with a $87 target.Markets DailyMBX Biosciences, Inc. (NASDAQ:MBX) Stock Has Consensus Target Price of $83.89 According to AnalystsAnalysts rate MBX Biosciences a Moderate Buy with a consensus price target of $87.00, though the stock opened at $49.61. The company missed Q2 earnings estimates with a loss of $0.78 per share versus a consensus of $0.68. Institutional investors have increased stakes, including Strs Ohio's 128.6% position increase.Ticker ReportMBX Biosciences (NASDAQ:MBX) Stock Price Expected to Rise, Stifel Nicolaus Analyst SaysStifel Nicolaus raised its target price on MBX Biosciences to $84 from $70, keeping a buy rating. The stock opened at $49, with an average analyst rating of Moderate Buy and a target of $87. The company reported a loss of $0.78 per share, missing estimates.